newscase

Iovance Shares Surge on Promising Lung Cancer Therapy Data

Iovance Biotherapeutics' stock experienced significant upward momentum following the release of encouraging interim results ...
MedCity News

Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer

A Roche cancer drug that treats lung cancer with a certain genetic signature now has an additional FDA approval that expands the applications of the blockbuster product. The drug, Alecensa, is already ...
Becker's Hospital Review

Medicaid expansion expedites lung cancer treatment

Patients in Medicaid expansion states had more timely treatment, a study from the Houston-based University of Texas MD Anderson Cancer Center found. The study, published April 11 in The Annals of ...
Nasdaq

FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer

AstraZeneca AZN announced that the FDA has expanded the label of its cancer drug Datroway for a second indication — non-small cell lung cancer (NSCLC). The drug has been developed in partnership with ...
Seeking Alpha

Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer

Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patients Expansion based on safety and strong initial efficacy results Data ...
Healio

Medicaid expansion linked to reduced mortality after lung cancer surgery

Please provide your email address to receive an email when new articles are posted on . Medicaid expansion reduced postoperative mortality rates for patient with NSCLC. In-hospital mortality after ...
Business Wire

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first ...
ksn.com

Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

AUSTIN, Texas, Feb. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients ...
ascopubs.org

Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient ...

We conducted a retrospective, difference-in-differences study including minority patients with nonmetastatic breast, colon, non–small-cell lung, and prostate cancer and patients treated at MSHs ...
Seeking Alpha

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer

Expansion of 2021 clinical supply agreement for Phase 2 clinical trial Next stage of trial to further assess efficacy of THIO in third line non-small cell lung cancer patients MAIA expects new patient ...

A2 Biotherapeutics Presents Initial Safety and Efficacy Data from Ongoing Phase 1/2 EVEREST-2 Study, Including First Report of a Complete Response to CAR T-Cell Ther…

A2 Biotherapeutics Presents Data from EVEREST-2 Study, Including First Report of a Complete Response to CAR T-Cell Therapy in ...